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Dawn.Livingstone@ed.ac.ukAbstractPatients with critical illness or hepatic failure exhibit impaired cortisol responses to ACTH,
a phenomenon known as ‘relative adrenal insufficiency’. A putative mechanism is that elevated
bile acids inhibit inactivation of cortisol in liver by 5a-reductases type 1 and type 2 and
5b-reductase, resulting in compensatory downregulation of the hypothalamic–pituitary–
adrenal axis and adrenocortical atrophy. To test the hypothesis that impaired glucocorticoid
clearance can cause relative adrenal insufficiency, we investigated the consequences of
5a-reductase type 1 deficiency in mice. In adrenalectomised male mice with targeted disruption
of 5a-reductase type 1, clearance of corticosterone was lower after acute or chronic (eightfold,
P!0.05) administration, compared with WTcontrol mice. In intact 5a-reductase-deficient male
mice, although resting plasma corticosterone levels were maintained, corticosterone responses
were impaired after ACTH administration (26% lower, P!0.05), handling stress (2.5-fold lower,
P!0.05) andrestraint stress (43%lower,P!0.05) comparedwith WTmice. mRNA levelsofNr3c1
(glucocorticoid receptor), Crh and Avp in pituitary or hypothalamus were altered, consistent
with enhanced negative feedback. These findings confirm that impaired peripheral clearance
of glucocorticoids can cause ‘relative adrenal insufficiency’ in mice, an observation with
important implications for patients with critical illness or hepatic failure, and for patients
receiving 5a-reductase inhibitors for prostatic disease.Key Words
" glucocorticoids
" 5a-reductases
" adrenal insufficiency
" HPA axisicen
.0 UJournal of Endocrinology
(2014) 222, 257–266IntroductionActivation of the hypothalamic–pituitary–adrenal (HPA)
axis is a vital component of the stress response, driving
production of glucocorticoid hormones (cortisol in
humans, corticosterone in rodents) that mediate essential
adaptations of the immune, metabolic and cardiovascular
systems in response, for example, to infection or injury.
Paradoxically, low cortisol concentrations have been
observed in patients with critical illness, particularly
after administration of synthetic adrenocorticotrophic
hormone (ACTH); this phenomenon has been termed
‘relative adrenal insufficiency’ and has led patients beingtreated with hydrocortisone (Annane et al. 2002). Similarly
impaired cortisol responses to synthetic ACTH have been
observed in patients with liver disease (Harry et al. 2002,
Fernandez et al. 2006, Tsai et al. 2006). The mechanisms
involved in these altered cortisol responses are complex,
with abnormalities observed in central HPA axis drive,
adrenal steroidogenesis and plasma protein binding
(Cooper & Stewart 2009). In addition, recent observations
have indicated that a key contribution results from
alterations in the enzymatic clearance of cortisol. In liver
disease, inactivation of cortisol by the enzymessed under a Creative Commons
nported License.
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222 :2 2585b-reductase (Akr1d1) and 11b-hydroxysteroid dehydro-
genase type 2 (Hsd11b2; Frey 2006, McNeilly et al. 2010)
is impaired. In critical illness, we have recently reported
profoundly impaired clearance of cortisol, which was
attributed to impaired 5a-reductase and 5b-reductase
activity in liver and Hsd11b2 in kidney (Boonen et al.
2013). We also demonstrated an association between
impaired cortisol clearance and a reduced cortisol response
to synthetic ACTH. As endogenous ACTH levels were
paradoxically low in critically ill patients, we proposed
the hypothesis that substantially slower clearance of
cortisol results in enhanced negative feedback suppression
of ACTH and hence compensatory downregulation of
cortisol production to maintain cortisol levels (Boonen
et al. 2013). As a result, adrenal atrophy ensues and the
incremental response to exogenous ACTH is impaired.
However, in disease settings, it is difficult to confirm the
primary cause of changes in HPA axis function.
An influence of peripheral steroid metabolism on HPA
responses has been demonstrated in mice unable to
regenerate or inactivate active glucocorticoid by Hsd11b1
orHsd11b2 respectively (Kotelevtsev et al. 1997, 1999, Harris
et al. 2001, Carter et al. 2009). Patients with impaired cortisol
clearance due to Hsd11b2 deficiency have reduced total
cortisol production, presumably through suppression of the
HPA axis (Stewart et al. 1988), which is mirrored inHsd11b2
knockout mice (Kotelevtsev et al. 1999). In contrast, mice
unable to regenerate tissue glucocorticoids due to deletion
of Hsd11b1 or hexose-6-phosphate dehydrogenase exhibit
adrenal hypertrophy (Kotelevtsev et al. 1997, Harris et al.
2001, Lavery et al. 2006, Carter et al. 2009). This again is
consistent with the clinical scenario, where enhanced
cortisol clearance in patients with rare Hsd11b1 or hexose-
6-phosphate dehydrogenase deficiency results in increased
ACTH drive to the adrenals, and hence elevated adrenal
androgens (Taylor et al. 1984, Phillipov et al. 1996, Jamieson
et al. 1999, Draper et al. 2003).
5a-Reductases are responsible for one-third to a half of
total peripheral glucocorticoid clearance, but their partici-
pation in the regulatory feedback loops mediated via the
HPA axis has not been studied. Upregulation of 5a-reductase
has been invoked to explain adrenal androgen excess in
polycystic ovary syndrome (Stewart et al. 1990, Fassnacht
et al. 2003, Tsilchorozidou et al. 2003). Although congenital
deficiency of 5a-reductase is rare (Imperato-McGinley et al.
1974), an increasing number of men are prescribed
5a-reductase inhibitors for benign prostatic hyperplasia.
The consequences, if any, for the HPA axis are unknown. We
tested, in a mouse model, whether deficiency of 5a-reductase
1 (Srd5a1) activity causes relative adrenal insufficiency.http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-13-0563
 2014 The authors
Printed in Great BritainMaterials and methods
Chemicals were obtained from Sigma unless otherwise
stated.In vivo protocols
Mouse embryos with targeted disruption of Srd5a1
(Mahendroo et al. 1996, 1997) (C57Bl6/SvEv/129 mixed
background; JacksonLaboratory, BarHarbor, ME,USA), were
re-derived (University of Edinburgh) and heterozygote
offspring crossed to generate homozygote male ‘WT’ and
‘knock-out’ (Srd5a1-KO) mice that were used for study at 4–5
months of age. All experiments were carried out under UK
Home Office license and mice were housed singly for 1 week
prior to investigations.Mice were maintained withad libitum
access to standard chow (Special Diet Services, Witham, UK)
under regulated conditions of light and darkness (lights on
from 0700 to 1900 h). Following killing by decapitation,
trunk blood was collected and one adrenal gland and the
thymus gland were removed and formalin-fixed. The
hypothalamus, remaining brain, pituitary and other adrenal
werefrozenonsoftdry ice.All sampleswerestoredatK80 8C.
Glucocorticoid clearance Weight matched (approxi-
mately 30 g) male WT and Srd5a1-KO mice were adrenal-
ectomised under isoflurane anaesthesia to remove
endogenous glucocorticoids (nZ8/group). After 2 weeks
recovery, mice received corticosterone (2 mg, in 10% ethanol
with 0.025% b-cyclodextrin) by s.c. bolus injection and
blood samples were obtained by tail-tip bleed after 0, 15, 30,
60 and 90 min.
In another group of mice, osmotic minipumps were
implanted subcutaneously during adrenalectomy to admin-
ister corticosterone for 3 weeks before mice were killed
(100 mg/day corticosterone in 1:1 DMSO:propylene glycol;
Alzet model 2004, Charles River UK Ltd, Margate, Kent, UK).
Clearance of corticosterone was calculated as the infusion
rate divided by the steady-state plasma concentrations
determined in trunk blood samples collected at killing.
Further intact WT and Srd5a1-KO mice (nZ12/group)
received corticosterone (50 mg/day) for 2 weeks by mini-
pump as indicated earlier. Mice were killed by decapitation
and trunk blood was collected.
Responses to stress Mice (nZ8/group) were killed
10 min following cage disturbance and handling. Trunk
blood was collected and brains were harvested.
The remaining mice (nZ12–18/genotype) were
removed from their home cage at 0800 h with minimumPublished by Bioscientifica Ltd
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222 :2 259disruption and blood was obtained rapidly (within 30 s) by
tail-nick. The animals were subsequently restrained within
Plexiglas restraint tubes for 15 min and another set of
blood samples was taken. They were returned to their
home cages and a further blood samples obtained either at
30, 60 or 90 min following the start of the restraint stress
(nZ6/time point). Blood samples were collected at only
one time point following the end of the restraint stress to
avoid confounding effects of repeated stress.
Responses to dexamethasone and ACTH Male mice
(nZ9–10/genotype) received an injection of dexametha-
sone (not a substrate for Srd5a1 (McGuire et al. 1960),
10 mg/kg body weight intra-peritoneally) at 1300 h to
achieve partial (approximately 50%) suppression of the
HPA axis. Blood samples were obtained by tail-nick at
1500 h, after which mice received injections of either
vehicle (saline) or ACTH (Synacthen diluted in saline,
Alliance, Chippenham, UK, 0.1 mg/kg; EC50) and blood
samples were again collected after 30 min.Laboratory protocols
Morphometric analysis of adrenal glands Fixed adrenal
glands (nZ8–14) were sectioned (5 mm), stained with
haematoxylin and eosin and examined by light
microscopy (Zeiss Axioscope, 40! magnification). The
cells were photographed using a Cool Snap Photometrics
camera and the number of cells in a given area (w160 mm2
for the inner and outer zona fasciculata and 40 mm2 for the
zona glomerulosa and zona reticularis) from each adrenal
was counted using MCID 7.0 software. The adrenals were
analysed in a randomised order by an observer blinded
to the genotype. Two areas were examined in two slices
from each adrenal and the mean values were calculated.Table 1 Assay details for real-time PCR. ABI assay numbers: cycloph
receptor 1 (Crhr1), Mm00432670_m1; 11b-hydroxylase (Cyp11b1), M
Forward primer
18S ribosomal RNA (Rn18s) ctcaacacgggaaacctc
b-actin (Actb) ctaaggccaaccgtgaaa
5a-reductase 1 (Srd5a1) gggaaactggatacaaa
5a-reductase 2 (Srd5a2) cgcacattacttccacagg
5b-reductase (Akr1d1) gaaaagatagcagaag
11b-hydroxysteroid dehydrogenase 1
(Hsd11b1)
tctacaaatgaagagttc
Glucocorticoid receptor (Nr3c1) gacgtgtggaagctgta
Arginine vasopressin (Avp) gctgccaggaggagaa
TATA box-binding protein (Tbp) gggagaatcatggacca
GAPDH gggttcctataaatacgg
http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-13-0563
 2014 The authors
Printed in Great BritainCryosections (10 mm) of frozen adrenals were stained
with Oil Red O to visualise lipid distribution and examined
by microscopy.
Quantification of mRNAs by real-time quantitative
PCR Adrenals (nZ11–14/genotype), hypothalami and
pituitaries (nZ6/genotype) were homogenised using a
QIAshredder column (Qiagen Ltd) and total RNA was
extracted from snap-frozen tissue samples using the
Qiagen RNeasy system, and 500 ng total RNA were reverse
transcribed into cDNA with random primers using the
QuantiTect DNase/reverse Transcription Kit. cDNA
(equivalent to 1 ng total RNA) was incubated in triplicate
with gene-specific primers and fluorescent probes
(Table 1: Applied Biosystems or the Universal Probe
Library, Roche Diagnostics) in 1! Roche LightCycler
480 Probes mastermix. PCR cycling and detection of
fluorescent signal were carried out using a Roche Light-
Cycler480. A standard curve was constructed for each set
of primer probes using a serial dilution of cDNA pooled
from all samples. The results were corrected for the mean
of abundance of reference genes (Gapdh and Tbp in the
hypothalamus, Rn18s, Tbp and Actb mRNAs for adrenal
with Ppia in addition for pituitary); the respective means
of the reference genes did not differ between groups.
Quantification of mRNAs by in situ hybridisation Cryo-
sections (10 mm) of brains (nZ8–9/group) were mounted
onto electrostatic slides. Antisense and sense riboprobes
for Nr3c1, Nr3c2 and Crh transcripts were prepared as
described previously (Harris et al. 2001). Tissues were
processed and hybridised, probes visualised by autoradio-
graphy and quantified using a microcomputer imaging
system operated by Zeiss KS300 3.0 computer software.
Nr3c1 and Nr3c2 transcripts were quantified in the dentateilin (Ppia), Mm02342429_g1; corticotrophin-releasing hormone
m01204952_m1
Reverse primer UPL probe no.
ac cgctccaccaactaagaacg 77
ag accagaggcatacagggaca 64
ataccc ccacgagctccccaaaata 41
a cagaaagatcaccgctgataaa 34
ggaaggt gggacatgctctgtattccataa 79
agaccag gccccagtgacaatcacttt 1
aagt catttcttccagcacaaaggt 56
ctac aaaaccgtcgtggcactc 84
gaa gatgggaattccaggagtca 97
actgc ccattttgtctacgggacga 52
Published by Bioscientifica Ltd
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222 :2 260gyrus (DG), CA1, CA2, CA3 and CA4 regions of the
hippocampus and Crh transcripts in the paraventricular
nucleus of the hypothalamus PVN, by counting of
the number of silver grains in each region by a blinded
observer, reporting the mean counts from six randomly
selected areas (radiusZ43 mm) minus background count.
Biochemical assays Velocities of hepatic Akr1d1 and
Hsd11b1 were quantified in tissue homogenates as
reported previously (Livingstone et al. 2009). Plasma
corticosterone was measured by an in-house RIA, without
significant cross-reactivity with dexamethasone (Holmes
et al. 1995), and ACTH by RIA (MP Biomedical, California,
CA, USA).
To quantify tissue corticosterone, liver (approxi-
mately 300 mg) was homogenised (3 ml, 7:2 methanol:-
water) and enriched with 125 ng epi-cortisol as internal
standard. The homogenates were shaken (15 min) and
centrifuged (3200 g, 45 min at 4 8C), the supernatant was
reduced to dryness under oxygen-free nitrogen (OFN,
60 8C) and then dissolved in 1:1 methanol:hexane
(20 ml). The methanolic layer was reduced to dryness
under OFN; the residue was dissolved in water (400 ml)
and steroids were extracted with ethyl acetate (ten
volumes). Organic extracts were dried under OFN; the
residue was dissolved in 30% methanol (5 ml) and then
applied to Megabond columns (2 g, C18, Varian, Oxford,
UK) and steroids were eluted with methanol (5 ml). The
eluate was dissolved in mobile phase (methanol:water
50:50 containing 0.1% formic acid) and steroids were
analysed by liquid chromatography tandem mass spec-
trometry using a Surveyor pump and TSQ Quantum
Discovery triple quadropole mass spectrometer (Thermo
Electron, Hemel Hempstead, UK). Steroids were separated
using a Kinetex PFP column (100!3 mm, 2.6 mm, 15 8C;
Phenomenex, Macclesfield, UK) using gradient elution;
initial conditions of methanol:water 50:50, each with
0.1% formic acid, were maintained for 1 min and then
programmed to achieve 35:65 (1–2.5 min), 30:70
(2.5–6 min) and 10:90 (6–6.5 min). The mass spec-
trometer was operated in a positive electrospray ionis-
ation mode with selected reactions monitoring
(transition, collision energy, tube lens: corticosterone;
m/z 347/121, 27 V, 103 V epi-cortisol m/z 363/121,
30 V, 95 V). The peak areas were integrated using
Xcalibur software (Thermo Electron) and corticosterone
was quantified as a proportion of epi-cortisol as
internal standard against a calibration curve. The
limit of detection was less than 1 ng corticosterone.
Corticosterone concentrations are presented corrected forhttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-13-0563
 2014 The authors
Printed in Great Britaintotal tissue weight. For brain steroid measurement, half
brains (sagitally sectioned) were homogenised in 1 ml
ethyl acetate:ethanol (1:1 v/v), the homogenate was
dripped into 10 ml ice-cold ethanol:acetic acid:water
(95:3:2 v/v) and incubated at K20 8C overnight. The
samples were then processed in the same way as for liver
homogenates.Statistical analysis
Data are meanGS.E.M. and were compared by Student’s
t-test or repeated measure ANOVA with Fisher’s post hoc
test as appropriate. Area under the curve was calculated
using Kinetica software (Thermo Electron). P!0.05 was
considered statistically significant.Results
Srd5a1-KO mice have decreased clearance of
corticosterone
Clearance of corticosterone was slower in Srd5a1-KO mice
compared with WT mice (3.42G0.61 vs 30.15G
11.75 ml/min; P!0.05), demonstrated by higher circulat-
ing corticosterone concentrations after both an acute
bolus (Fig. 1A) and chronic infusion (Fig. 1B) of corticos-
terone in adrenalectomised mice. Residual corticosterone
was detectable in adrenalectomised mice, but the levels
were not different between genotypes. Slower clearance
was also reflected in higher liver (Fig. 1C) and brain
(Fig. 1D) corticosterone concentrations in Srd5a1-KO mice
following chronic corticosterone infusion. The velocities
of hepatic Hsd11b1 and Akr1d1 were not different between
Srd5a1-KO and WT mice (11.7G0.8 vs 13.4G0.5 nmol/mg
per h, 244G22 vs 299G32 pmol/mg per h, respectively),
and this was also reflected in the abundances of the
transcript for Hsd11b1 (0.86G0.16 vs 1.05G0.11),
although mRNA encoding Akr1d1 was present at lower
levels in Srd5a1-KO mice than in WT controls (0.54G0.03
vs 0.90G0.15; PZ0.04).Resting plasma corticosterone levels are maintained in
intact Srd5a1-KO mice
There were no differences between Srd5a1-KO and WT
mice in basal (unstressed) circulating corticosterone at the
diurnal nadir (Fig. 2A). Intact Srd5a1-KO mice adapted
appropriately to corticosterone infused at sub-physio-
logical replacement dose, maintaining the same total
circulating corticosterone concentrations as WT micePublished by Bioscientifica Ltd
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Figure 1
Clearance of corticosterone in Srd5a1-KO and WT mice. Plasma cortico-
sterone concentrations following (A) corticosterone bolus injection and
(B) chronic infusion were higher in adrenalectomised mice deficient in
5a-reductase 1 (KO, open circles/white bars) than in WT mice
(WT, black squares/bars). Amounts of corticosterone in (C) liver and
(D) brain were higher in KO than in WT mice following chronic infusion
of corticosterone. *P!0.05 versus WT.
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222 :2 261(Fig. 2B). The ACTH level measured in trunk blood was not
different between Srd5a1-KO and WT mice (208.4G49.4 vs
125.5G24.3 pg/ml; PZ0.13, nZ17–18).
Weights of the adrenal and thymus glands were not
different between genotypes (Table 2). Gross morpho-
metric examination of the adrenal glands did not reveal
any differences (Fig. 3A and B). Neither the number of cells
per unit area (Fig. 3C, D, E, F, G, H, and K), the distribution
of lipid by Oil Red O staining (Fig. 3I and J), nor the
abundance of adrenal mRNA encoding Cyp11b1 (0.46G
0.05 vs 0.43G0.05) differed between genotypes.5aR1-KO mice exhibit ‘relative adrenal insufficiency’
during stimulation by stress or ACTH
Corticosterone levels were suppressed to a similar
degree in response to a sub-maximal dose of dexametha-
sone (Fig. 4A). Following exogenous ACTH adminis-
tration, the increase in plasma corticosterone
concentrations was attenuated in Srd5a1-KO mice
compared with WT (Fig. 4A). Circulating corticosterone
levels were lower in Srd5a1-KO than in WT mice, in
response to both minor stress (cage disturbance and
handling; Fig. 4B) and after restraint stress (Fig. 4C; area
under the curve for plasma corticosterone (10.3G2.2 vs
18.0G2.0 mM.min, PZ0.003).Table 2 Characteristics of Srd5a1-KO and WT mice. Data are
meanGS.E.M. nZ12–16/group
WT 5aR1-KO
Body weight (g) 26.3G0.85 27.0G0.76
Adrenal weight (mg) 2.2G0.08 2.1G0.09
Adrenal weight/body weight (mg/g) 0.17G0.01 0.16G0.01
Thymus weight (mg) 40.4G3.3 39.2G3.5
Srd5a1-KO, 5a-reductase 1 knockout.
http://joe.endocrinology-journals.org
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Printed in Great BritainThe molecular control of the HPA axis compensates for
altered corticosterone clearance in Srd5a1-KO mice
Pituitary and brain transcript abundances are shown in
Fig. 5. In Srd5a1-KO mice, glucocorticoid receptor (Nr3c1)
transcripts were more abundant in the pituitary and hypo-
thalamusbutnot inany regionsof thehippocampus (Fig.5A,
C, and D). Mineralocorticoid receptor (Nr3c2) transcripts in
the hippocampus were also unaffected by genotype (Fig. 5E).
Corticotrophin-releasing hormone receptor 1 (Crh-r1)
transcript abundance in pituitary was not different between
genotypes (Fig. 5A); however,CrhmRNA in the PVN (Fig. 5B)
and arginine–vasopressin (Avp; Fig. 5C) mRNAs in the
hypothalamus were both lower in abundance in 5aR1-KO
than inWTmice.Representative imagesof the in situanalysis
are shown in Supplementary Figure 1, see section on
supplementary data given at the end of this article.Discussion
These data confirm that the enzyme Srd5a1 contributes
in large part to glucocorticoid clearance in mice, and that
its targeted disruption is sufficient to induce a phenotype
analogous to ‘relative adrenal insufficiency’ in patients
with impaired cortisol clearance. Although baseline
plasma ACTH and corticosterone are normal, mice lacking
Srd5a1 exhibit not only impaired corticosterone responses
to ACTH but also impaired responses to mildly and
moderately stressful stimuli. Moreover, this occurred in
the absence of any demonstrable primary histological
abnormality in the adrenal glands and was associated with
alterations in neuroendocrine signalling pathways in
the hypothalamus and pituitary that are most readily
explained by enhanced negative feedback by corticoster-
one resulting from its impaired peripheral clearance and
causing a compensatory downregulation of the HPA axis.Published by Bioscientifica Ltd
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Plasma corticosterone in Srd5a1-KO and WT mice. Basal plasma cortico-
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similar to the situation in humans, and therefore deficiency
at this site predicts impaired peripheral metabolism, as
observed in the experiment involving chronic infustion of
corticosterone. However 5a-reductases are expressed also
in brain (Lephart 1993a), specifically in the hypothalamus
(Thigpen et al. 1993, Lund et al. 2006) (where Srd5a1 is more
abundant than Srd5a2 (Lephart 1993b)) and to a lesser extent
inpituitary (Lephart1993b).Deficiencyor inhibitionof5aR1
at these sites may attenuate local inactivation of glucocorti-
coids, and thereby enhance negative feedback suppression
of the HPA axis independently of the altered peripheral
clearance. Following chronic infusion of corticosterone, we
did not find a disproportionate elevation in brain corticos-
terone levels in Srd5a1-KO mice; the elevation in brain
corticosterone levels was of a similarmagnitude to thehigher
plasma corticosterone levels in Srd5a1-KO mice. Further-
more, the observation that plasma ACTH in unstressed
animals is not suppressed by 5aR1 deficiency indicates that
theprimarydriver for alteredHPAaxis function lies inaltered
peripheral corticosterone clearance rather than failure of
corticosterone inactivation in the brain.
The modulatory role of ligand concentrations on
glucocorticoid and mineralocorticoid receptors (Nr3c1 and
Nr3c2) at feedback sites within the HPA axis has been studied
in other rodent models. In the extreme scenario of
adrenalectomy, mice have dramatically higher ACTH levels,
along with greater Nr3c1 abundance at feedback sites (Han
et al. 2007), the receptor apparently auto-regulating in
response to absence of ligand (Herman & Spencer 1998, Ing
2005). The converse is true with chronic stress associated
with elevated glucocorticoids, suppressing GR levels in the
PVN but not in the hippocampus (Makino et al. 1995).http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-13-0563
 2014 The authors
Printed in Great BritainHowever, inmodelsofmoresubtlemodulationof ligand,e.g.
in mice with increased peripheral clearance induced by
Hsd11b1 deficiency, changes in Nr3c1 expression may not
auto-regulate in the same manner. On a 129/MF1 genetic
background, mice lacking Hsd11b1 develop a greater degree
of adrenal hypertrophy (approximately 70%) (Harris et al.
2001) than on a C57BL/6 background (approximately 20%)
(Carter et al. 2009).This appears to beattributable to C57BL/6
mice being better able than 129/MF1 mice to upregulate
Nr3c1 at central feedback sites, contributing to resetting of
the HPA axis (Carter et al. 2009). Specifically, in the mixed
strain 129/MF1 Hsd11b1-deficient mice with more pro-
nounced HPA abnormalities, exaggerated peripheral gluco-
corticoid clearance was accompanied by suppressed Nr3c1
expression in the PVN. Against this background, our findings
are consistent with impaired peripheral glucocorticoid
metabolism in Srd5a1-KO mice bred on a mixed genetic
background (comprising C57Bl6/SvEv/129), with an upre-
gulation of Nr3c1 transcript in central feedback sites
(Mahendroo et al. 1997). Increased Nr3c1 action may be
associated with downregulation of transcription of Crh
(Malkoski & Dorin 1999) and Avp (Burke et al. 1997)
mRNAs in the hypothalamus, together mediating a com-
pensatorydownregulationof stress-inducedACTHsecretion.
Similar downregulation of hypothalamicCrh transcripts has
been demonstrated in vivo in mice with increased gene
dosage ofNr3c1 (Reichardt et al. 2000). However, any change
in Nr3c1-mediated signalling with manipulation of Srd5a1
appears too subtle to be detected by dexamethasone
suppression testing in mice. Furthermore, basal circulating
corticosterone levels were unaltered by disruption of Srd5a1,
and intact mice adapted appropriately to the infusion of low
physiological levels of glucocorticoid. Overall these data
indicate that a centrally driven primary abnormality of the
HPA axis causing relative adrenal insufficiency is unlikely
and that the phenotype is most probably driven by impaired
peripheral metabolic clearance of corticosterone.
Although our investigations focused on glucocorti-
coids, 5a-reductases also metabolise a wide range of other
steroid hormones, some of which may have important
effects on the CNS. Androgens can repress CRH (Bao et al.
2006), but lack of the most potent androgen 5a-dihy-
drotestosterone (DHT) would predict a more, rather than
less, dynamic HPA axis with deficiency of Srd5a1.
Reduction of testosterone to DHT by Srd5a1 is also
thought to regulate the feedback responses of GNRH
neurons to androgens (Tobyn & Canny 1998), which we
did not investigate here. 5a-Reduced neurosteroids
(e.g. allopregnanolone) have been implicated in the
attenuation of behavioural responses to anxiety, actingPublished by Bioscientifica Ltd
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Figure 3
Morphological analysis of adrenal glands from WT and 5aR1-KO mice.
Representative sections (5 mm) of adrenal glands stained with haemato-
xylin and eosin. Gross histological (10! magnification) differences
between (A) WT mice and (B) those deficient in 5a-reductase 1 (KO) were
not observed. Individual zones are shown at higher magnification (40!):
(C and F) zona glomerulosa; (D and G) zona fasciculata and (E and H) zona
reticularis in WT and KO mice respectively. Panels I (WT) and J (KO) show
representative sections (5 mm) of frozen adrenal glands stained with
Oil red O and photographed at 10! magnification; differences in lipid
accumulation were not observed. Panel K shows the number of cells per
zone of the adrenal gland in WT (black bars) and KO (white bars) mice.
Significant changes in the number of cells in any of the adrenal zones were
not observed between genotypes. M, adrenal medulla; ZG, zona
glomerulosa; ZF, zona fasciculata; IZF, inner zona fasciculata; OZF, outer
zona fasciculata; ZR, zona reticularis. nZ6–8/group per treatment.
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222 :2 263via the GABA-A receptors to reduce neuronal excitability;
this may impinge upon the HPA axis and attenuate stress
responses, as is most apparent during late pregnancy
(Russell & Brunton 2006).
These findings may be relevant to clinical practice. It is
notable that in Srd5a1-KO mice corticosterone clearance
was reduced by approximately 80% compared with that of
WT mice; this was attributed to changes in 5a-reduction
as the velocities of hepatic Akr1d1 and Hsd11b1 were
unaltered (despite a modest reduction in Akr1d1 mRNA).
Findings in Srd5a1-KO mice were therefore rather larger
in magnitude than the approximately 50% reduction in
cortisol clearance we demonstrated in critically ill patientshttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-13-0563
 2014 The authors
Printed in Great Britainduring infusion of deuterated-cortisol (Boonen et al. 2013),
especially considering that critically ill patients have ‘extra’
loss of cortisol-clearing capacity attributed to reduced
activity of Akr1d1 and Hsd11b2. It may be that Srd5a1
contributes more to glucocorticoid clearance in mice than
it does in humans, which is plausible as 5a-reductase type 1
is the only isozyme expressed in mouse liver (Mahendroo
et al. 1996, 1997) whereas human liver contains both
5a-reductase type 1 and type 2 (Evans & Goa 2003).
These data indicate that there may be a risk of inadequate
cortisol responses to stress in men taking 5a-reductase
inhibitors for prostatic disease, particularly when the dual
5a-reductase type 1 plus type 2 inhibitor, dutasteride, isPublished by Bioscientifica Ltd
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Figure 4
Dynamic responses of the hypothalamic–pituitary–adrenal axis to stimu-
lation and suppression. (A) Circulating concentrations of corticosterone
were not different between mice deficient in Srd5a1 (KO, open
circles/white bars) and WT mice (WT, black squares/bars), following partial
suppression of the hypothalamic–pituitary–adrenal axis with dexametha-
sone, but the corticosterone response to ACTH stimulation was attenuated
in KO mice compared with WT (by two-way ANOVA, P!0.01 for effect of
ACTH and P!0.05 for effect of genotype). (B) Circulating corticosterone
levels were lower in KO mice following mild handling stress than in WT
mice. (C) The increase in corticosterone in response to 15 min acute
restraint stress (indicated by dark bar on graph) was attenuated in KO mice
(open circles) compared with WT mice (black squares) (nZ12–18/genotype
at tZ0 and 15 and nZ6 at other time points; P!0.01 for change with time
and P!0.05 for genotype effect by repeated measures ANOVA). Unless
stated, nZ6–8/group per treatment. *P!0.05 vs WT.
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222 :2 264prescribed in preference to the selective type 2 inhibitor,
finasteride. Previous investigations following inhibition of
5a-reductases in humans indicate that women, who are
sometimes treated with finasteride for hirsutism, do exhibit
changes in the HPA axis (Fruzzetti et al. 1994), at least for a
short-term period, with decreased basal plasma cortisol and
an impaired cortisol response to exogenous ACTH. However,
studies in men have shown no change in basal cortisol
(Rittmaster et al. 1994, Lewis et al. 1997, Uygur et al. 1998) or
in response to high dose ACTH (Rittmaster et al. 1994),50
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Figure 5
Transcript abundances of genes regulating the hypothalamic–pituitary–
adrenal axis. (A) In pituitary, abundance of transcripts for glucocorticoid
receptor (GR) but not corticotrophin releasing hormone receptor 1 (Crhr1)
was higher in mice deficient in Srd5a1 (KO; black bars) compared with WT
controls (WT; white bars). In the paraventricular nucleus of the hypo-
thalamus, the transcripts of (B) Crh and (C) arginine–vasopressin (Avp) were
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Printed in Great Britainalthough a lower, potentially more discriminatory dose has
not been tested. Administration of 5a-reductase inhibitors to
men suppresseses daily total glucocorticoid production rates
by approximately 20% (Upreti et al.2014), but the proportion
of cortisol excreted in urine as 5a-reduced metabolites is
substantially higher in women than in men (Andrew et al.
1998), consistent with 5a-reductases making a greater
contribution to clearance of cortisol. In women, this may
be attributable to Srd5a2 rather than Srd5a1 in liver, because
effects on the HPA axis consistent with altered cortisol50
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lower in KO mice compared with WT, while Nr3c1 transcript
was higher. In the CA1, CA2, CA3, CA4 regions or dentate gyrus
(DG) of the hippocampus, differences were not observed between
genotypes in abundances of transcripts of (D) Nr3c1 or (E) mineralocorti-
coid receptors (Nr3c2). Data are meanGS.E.M., HK, housekeeping genes;
nZ6–9/group. *P!0.05 vs WT.
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222 :2 265clearance were observed with the selective type 2 inhibitor
finasteride (Fruzzetti et al. 1994). Thus, women may be more
susceptible than men to ‘relative adrenal insufficiency’ if
given a 5a-reductase inhibitor.
In conclusion, our findings emphasise that peripheral
steroid metabolism has potentially potent effects on the
HPA axis. In mice with life-long deficiency of Srd5a1,
adrenal responsiveness to stress is substantially impaired.
This may have implications for individuals receiving
5a-reductase inhibitors chronically, and particularly for
women in whom the 5a-reductase pathway of cortisol
metabolism is thought to be of greater significance than in
men. Our data confirm the hypothesis that ‘relative adrenal
insufficiency’ can result from impaired glucocorticoid
clearance, which appears to be relevant in many clinical
scenarios, including hepatic failure and critical illness.Supplementary data
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